Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/194216
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jiménez, Raquel | - |
dc.contributor.author | Rosiñol, Laura | - |
dc.contributor.author | Cibeira, María Teresa | - |
dc.contributor.author | Fernández de Larrea Rodríguez, Carlos José | - |
dc.contributor.author | Tovar, Natalia | - |
dc.contributor.author | Rodríguez-Lobato, Luis Gerardo | - |
dc.contributor.author | Bladé, Esther | - |
dc.contributor.author | Moreno, David F. | - |
dc.contributor.author | Oliver Caldés, Aina | - |
dc.contributor.author | Bladé, J. (Joan) | - |
dc.date.accessioned | 2023-02-27T16:40:28Z | - |
dc.date.available | 2023-02-27T16:40:28Z | - |
dc.date.issued | 2022-09-16 | - |
dc.identifier.issn | 2044-5385 | - |
dc.identifier.uri | http://hdl.handle.net/2445/194216 | - |
dc.description.abstract | From January 1970 to December 2018, 1304 patients were diagnosed with multiple myeloma (MM) at our institution and 256 (19.6%) had plasmacytomas (Ps) (paraskeletal -PPs- 17.6%, extramedullary -EMPs-1.9%). Patients with Ps had lower serum M-protein and less advanced ISS stage than those without. At first relapse, 192 out of 967 patients (19.8%) developed Ps (PPs 14.6%, EMPs 5.1%). The only factor associated with Ps at relapse was the presence of Ps at diagnosis (46% vs 13%, p < 0.00001) with no impact with exposure to novel drugs or previous autologous stem-cell transplantation (ASCT). The median overall survival (OS) was 45, 44 and 20 months for patients without Ps, PPs and EMPs, respectively (p = 0.013). Patients with PPs who underwent ASCT had similar OS than those without Ps (98 vs. 113 months) and significantly longer than those with EMPs (98 vs 47 months, p = 0.006). In patients non-eligible for ASCT the presence of PPs or EMPs was associated with shorter OS compared with patients without Ps (32 vs. 24 vs. 6 months, p = 0.009). In the relapsed setting, a significant survival benefit was observed beyond the year 2000, but still with significant differences among patients without Ps, PPs and EMPs (37 vs 22 vs 16 months, p = 0.003). Importantly, rescue therapy with combinations of proteasome-inhibitors plus immunomodulatory drugs was associated with prolonged OS from first relapse (over 6 years), even in patients with EMPs. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Springer Nature | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1038/s41408-022-00730-5 | - |
dc.relation.ispartof | Blood Cancer Journal, 2022, vol. 12, num. 9 | - |
dc.relation.uri | https://doi.org/10.1038/s41408-022-00730-5 | - |
dc.rights | cc-by (c) Jiménez, Raquel et al., 2022 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Mieloma múltiple | - |
dc.subject.classification | Diagnòstic de plasma | - |
dc.subject.classification | Cèl·lules canceroses | - |
dc.subject.classification | Estudi de casos | - |
dc.subject.other | Multiple myeloma | - |
dc.subject.other | Plasma diagnostics | - |
dc.subject.other | Cancer cells | - |
dc.subject.other | Case studies | - |
dc.title | Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 730848 | - |
dc.date.updated | 2023-02-27T16:40:28Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9329659 | - |
dc.identifier.pmid | 36114167 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
730848.pdf | 1.07 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License